News

FDA breakthrough therapy status helps in accelerating the development and review of drugs for serious or life-threatening conditions if preliminary clinical evidence indicates the therapy may show a

The Phase IIb trial, called AURA–LV (Aurinia Urine protein Reduction in Active Lupus with voclosporin) or AURA, is planned to be carried out in about 20 countries. The

The agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics. As part of the deal, Liomont will provide Oncobiologics with upfront licensing and

These two patents broadly cover methods and uses for AC-201 as monotherapy or in combination with other lipid lower agents to treat patients with type II diabetes and

Following the launch of Herceptin SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche’s oncology products using Halozyme’s patented EnhanzeTM (recombinant

The company’s Vice President of Sales Callum Baylis-Duffield said of the exemption, "As we gear up to commence marketing Phytofare in the coming quarter, qualifying for this exemption

The patent claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer. Prostate cancer typically

"DTCC" stands for "The Depository Trust Clearing Corporation." DTCC is a member of the U.S. Federal Reserve System. It is a limited trust company under New York State

Tumor types were selected based on clinical observations in the phase 1 study and a detailed analysis of potential patient stratification biomarkers across tumor indications. The study will